Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia

Atherosclerosis

Volumn 185, Issue 2, 2006, Pages 327-330

  Rosenson, Robert S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bile acid sequestrants; Colesevelam HCl; LDL particle number; LDL size; Lipoprotein subclasses

Indexed keywords

COLESEVELAM; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PARTICLE SIZE; TRIGLYCERIDES;

EID: 33644544672     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.05.032     Document Type: Article

References (12)

1. W.C. Cromwell, and J.D. Otvos Low-density lipoprotein particle number and risk for cardiovascular disease Curr Atheroscler Rep 6 2004 381 387
2. G.J. Blake, J.D. Otvos, N. Rifai, and P.M. Ridker Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women Circulation 106 2002 1930 1937
3. L. Kuller, A. Arnold, and R. Tracy Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 22 2002 1175 1180
4. J.D. Otvos, I. Shalaurova, D.S. Freedman, and R.S. Rosenson Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial Atherosclerosis 160 2002 41 48
5. G.J. Blake, M.A. Albert, N. Rifai, and P.M. Ridker Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial Eur Heart J 24 2003 1843 1847
6. M.H. Davidson, M.A. Dillon, and B. Gordon Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects Arch Intern Med 159 1999 1893 1900
7. A. Zambon, J.E. Hokanson, B.G. Brown, and J.D. Brunzell Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density Circulation 99 1999 1959 1964
8. J.L. Witztum, G. Schonfeld, S.W. Weidman, W.E. Giese, and M.A. Dillingham Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins Metabolism 28 1979 221 229
9. S.G. Young, J.L. Witztum, T.E. Carew, R.W. Krauss, and F.T. Lindgren Colestipol-induced changes in LDL composition and metabolism. II. Studies in humans J Lipid Res 30 1989 225 238
10. G.L. Vega, and S.M. Grundy Hypercholesterolemia with cholesterol-enriched LDL and normal levels of LDL-apolipoprotein B. Effects of the step I diet and bile acid sequestrants on the cholesterol content of LDL Arterioscler Thromb Vasc Biol 16 1996 517 522
11. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
12. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298